Details for New Drug Application (NDA): 020393
✉ Email this page to a colleague
The generic ingredient in ATROVENT is ipratropium bromide. There are eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
Summary for 020393
Tradename: | ATROVENT |
Applicant: | Boehringer Ingelheim |
Ingredient: | ipratropium bromide |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020393
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Oct 20, 1995 | TE: | RLD: | Yes |
Expired US Patents for NDA 020393
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | ATROVENT | ipratropium bromide | SPRAY, METERED;NASAL | 020393-001 | Oct 20, 1995 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription